September 30- October 3, 2024, Discovery on Target
1) Discovery and Development of pan-KRAS Degraders for Cancer Therapyn 2) Efficacy of a First-in-Class Polymerase Theta Degrader in Preclinical Cancer Models
September 1-5, 2024, XXVIII EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC 2024)
1) Distinctive Roles for Small Molecule Inhibitors of Immune Checkpoint Proteins (LE072) April 5- 10, 2024, AACR Conference
1) SMARCA 2/4 Degraders Relieve The Differentiation Block In AML via Changes In Chromatin Looping and Accessibility2) Paralogue Selectivity p300 Degraders Induce Synthetic Lethality in Pre-Clinical Models of CBP- Deficient April 1- 4, 2024, Drug Discovery Chemistry
1) A Highly Differentiated Small Molecule Immune Checkpoint Inhibitor Dually Targeting PD-L1 And A2AR for Cancer Therapy2) Targeting CBM, A Tri Protein Signalling Hub, by Inhibition Of MALT1 for theOctober 11-15, 2023, AACR- NCI- EORCT International Conference On Molecular Targets And Cancer Therapeutics
1) Identification of Paralogue Selective Degraders Of SMARCA2 And SMARCA4 for the Treatment of Various Cancers2) Discovery of Potent and Paralogue Selective PROTAC Degraders of CBP or P300 Proteins forSeptember 26-28, 2023, Discovery On Target
1) Targeting DDR1 Kinase to Address Tumor Dissemination, Immune Exclusion and Therapeutic Resistance2) Targeting CBP/P300 – Inhibition vs. Degradation for Potent Anti-Tumor EfficacyJune 8-11, 2023, European Hematology Association
1) A Phase 1, Open Label, Dose Escalation, First-in-Human (FIH) Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AUR-103 in Patients with Relapsed Advanced Malignancies (BHARAT-1)April 14 – 19, 2023, AACR
1) Generation of Profound Anti-Tumor Immunity by AUR-109, A Spectrum-Selective Tyrosine Kinase Inhibitor, Either as a Single Agent or in Combination with Immune Checkpoint Inhibitors2) A Highly Differentiated A2AR InhibitorApril 10-13, 2023, Drug Discovery Chemistry
1) Targeting CBP/p300 – Inhibition vs. Degradation for Potent Anti-Tumor Efficacy